Intas Pharmaceuticals

Ahmedabad, India
Find alternatives to Intas Pharmaceuticals for Cell Therapy →
Program data pending ClinicalTrials.gov matching · Last scored 2026-11-12
62.3
Signal Score
✓ FDA Inspections (3) ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ✓ MHRA GMP (5) ✓ HC GMP (38)

Quick Facts: Intas Pharmaceuticals

Signal Score
62.3/100 (as of 2026-11-12)
Quality Compliance
69.0/100 — OAI classification at Sanand (2022-12-02) — CRITICAL
Headquarters
Ahmedabad, India
Modalities
Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Intas Pharmaceuticals

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 69.0
OAI classification at Sanand (2022-12-02) — CRITICAL
OAI classification at Selaqui (2025-09-16) — CRITICAL
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Sources: FDA Data Dashboard, MHRA GMDP
OAI classification at Sanand (2022-12-02) — CRITICAL · OAI classification at Selaqui (2025-09-16) — CRITICAL · Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated · Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated · Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated · Clean MHRA record: 5 compliant GMP certificates (no deductions)
FDA Inspections3 on record
Warning Letters3
Last InspectionOfficial Action Indicated (OAI) (2025-09-16)
2023-11-21CGMP/Finished Pharmaceuticals/AdulteratedInspection 2023-05-01 to 2023-05-12, per the letter; letter signed 193 days after it ended. Not yet on FDA’s Data Dashboard.
2023-07-28CGMP/Finished Pharmaceuticals/AdulteratedInspection 2022-11-22 to 2022-12-02, per the letter; letter signed 238 days after it ended.
MHRA GMP Certificates5 on record
Health Canada Non-compliant2
Most Recent HC OutcomeCompliant · 2025-03-15
HC Attribution38 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
OAI classification at Sanand (2022-12-02) — CRITICAL
OAI classification at Selaqui (2025-09-16) — CRITICAL
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Warning Letter: CGMP/Finished Pharmaceuticals/Adulterated
Clean MHRA record: 5 compliant GMP certificates (no deductions)
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 53.0
1 manufacturing site: Ahmedabad, IN
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Ahmedabad, IN
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Ahmedabad, IN
Modalities: Cell Therapy
Capacity assessment: 53.0/100

Intas Pharmaceuticals FDA Inspection History

2025-09
2024-07
2022-12
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-09-16
Intas Pharmaceuticals Ltd.
Selaqui Company-level
Drug Quality Assurance Not posted Official Action Indicated (OAI)
2024-07-12
Intas Pharmaceuticals Limited
Ahmedabad Company-level
Bioresearch Monitoring Not posted No Action Indicated (NAI)
2022-12-02
Intas Pharmaceuticals Limited
Sanand Company-level
Drug Quality Assurance Yes Official Action Indicated (OAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Intas Pharmaceuticals FDA 483 Findings 11 observations · 2022-12-02 → 2022-12-02 ?

By subsystem

  • Laboratory Controls 3 (27.3%)
  • Documentation & Records 3 (27.3%)
  • CAPA 2 (18.2%)
  • Other 1 (9.1%)
  • Environmental Monitoring 1 (9.1%)
  • Data Integrity 1 (9.1%)

By severity

  • 5 — Critical: 1
  • 4 — Serious: 1
  • 3 — Moderate: 5
  • 2 — Minor: 4
  • Repeat observations: 0

Most severe findings

  • Critical (5) Data Integrity 2022-12-02 21 CFR 211.68(b)
    Computer control of master formula records

    "Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel."

  • Serious (4) Environmental Monitoring 2022-12-02 21 CFR 211.42(c)(10)(iv)
    Environmental Monitoring System

    "Aseptic processing areas are deficient regarding the system for monitoring environmental conditions."

  • Moderate (3) Laboratory Controls 2022-12-02 21 CFR 211.160(a)
    Following/documenting laboratory controls

    "Established test procedures and laboratory control mechanisms are not followed."

Intas Pharmaceuticals MHRA GMP Compliance 5 certificates

2025-03
2025-03
2024-02
2020-06
2018-01
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK GMP 17543 Insp GMP 17543/9621-0025 [H] INTAS PHARMACEUTICALS LIMITED IN-382210 2025-03-06 COMPLIANT
UK GMP 17543 Insp GMP 17543/9621-0025 [V] INTAS PHARMACEUTICALS LIMITED IN-382210 2025-03-06 COMPLIANT
UK GMP 17543 Insp GMP 17543/13361605-0002[H] INTAS PHARMACEUTICALS LIMITED IN 248197 2024-02-01 COMPLIANT
UK GMP 17543 Insp GMP 17543/18270974-0007[H] INTAS PHARMACEUTICALS LIMITED IN 382213 2020-06-23 COMPLIANT
UK GMP 17543 Insp GMP 17543/1682029-0005[H] INTAS PHARMACEUTICALS LIMITED IN-382213 2018-01-29 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

sterile · 1 site

  • India · Intas Pharmaceuticals Limited — sterile · valid to Apr 13, 2027 renewal due

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No count for this company yet. The careers board we can read covers more than this business (41 postings on Nov 20, 2026), and we can't yet tell which of those roles belong to it. Why: the board covers the whole group and doesn't say which business unit a role belongs to. We'd rather show no number than one that isn't really this company's.
Source: intasaccordcareers.com · Checked Nov 20, 2026

Frequently Asked Questions About Intas Pharmaceuticals

How many FDA inspections does Intas Pharmaceuticals have on record?
CDMO Signal tracks 3 FDA inspections for Intas Pharmaceuticals, sourced from the FDA inspection database. See the full inspection history above.
Has Intas Pharmaceuticals received an FDA warning letter?
Yes — CDMO Signal has 3 FDA warning letters on record for Intas Pharmaceuticals.
Does Intas Pharmaceuticals hold EMA or MHRA GMP certificates?
CDMO Signal tracks 5 MHRA GMP certificates for Intas Pharmaceuticals.
What is Intas Pharmaceuticals's CDMO Signal Score?
Intas Pharmaceuticals has a Signal Score of 62/100, based on quality, operations, financial stability, and capacity data.
Evaluating Intas Pharmaceuticals for a manufacturing program?
Use the free AI matchmaker to compare Intas Pharmaceuticals against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Cell Therapy CDMOs →

Similar CDMOs

Syngene International
Bengaluru, India
Signal Score: 80.3
Biologics, Cell Therapy
Biocon Biologics
Bengaluru, India
Signal Score: 75.7
Cell Therapy
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy

Compare Intas Pharmaceuticals with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Intas Pharmaceuticals
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.